In the article by Yiu et al, on page 331 it states that 844 patients were not included; three emigrated, 785 withdrew consent and 56 did not complete their questionnaire. Similarly, on page 335 it states that a total of 844 registered patients were classified as dropping out owing to lack of follow‐up. Of these patients, 92·5% (785 patients) discontinued the study owing to withdrawal of consent.
The correct reasons are 80.7% (681 patients) had not reached their first follow‐up, 15.7% (133 patients) did not attend their follow‐up clinics, and 3.6% (30 patients) moved to an unknown area or hospital or withdrew consent.
The authors apologise for the error.
Reference
- 1. Yiu ZZN, Ashcroft DM, Evans I et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 2019; 180:329–37. [DOI] [PMC free article] [PubMed] [Google Scholar]